Skip to main content

Displaying 1001 - 1020 of 4735

Elanco Animal Health and Bayer

In July 2020, the FTC required global suppliers of animal products, Elanco Animal Health, Inc. and Bayer Animal Health GmbH, to divest three animal health products to settle charges that Elanco’s proposed $7.6 billion acquisition of Bayer would likely be anticompetitive in those markets. On Sept. 11, 2020, the Commission announced the final consent agreement in this matter.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
191 0198
Docket Number
C-4725
Case Status
Pending

AbbVie Inc. and Allergan plc, In the Matter of

Pharmaceutical companies AbbVie Inc. and Allergan plc have agreed to divest assests to settle Federal Trade Commission charges that AbbVie's proposed $63 billion acquisition of Allergan would violate federal antitrust law. On Sept. 4, 2020, the Commission announced the final consent agreement in this matter.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
191 0169
Case Status
Pending

Eldorado Resorts and Caesars Entertainment, In the Matter of

Casino operator Eldorado Resorts, Inc. has agreed to divest assets to settle charges that its $17.3 billion acquisition of Caesars Entertainment Corporation likely would be anticompetitive in the South Lake Tahoe area of Nevada, the Bossier City-Shreveport area of Louisiana, and the Kansas City area of Kansas and Missouri. According to the complaint, the proposed acquisition would harm competition for casino services in these three local markets, increasing the likelihood that Eldorado would unilaterally exercise market power, which in turn would lead to higher prices and reduced quality. In August 2020, the Federal Trade Commission approved a final order resolving those charges.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
191 0158
Docket Number
C-4721
Case Status
Pending